uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market

 
• By Alaric DeArment
  
3-D Rendering Red Blood Cells
uniQure and CSL Behring announced positive Phase III data for EtranaDez in hemophilia B • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies